Last reviewed · How we verify
NCT04990752: Uli-ECMO
Effects of Ulinastatin on Inflammatory Response During ECMO Support
trial testing ulinastatin in ECMO in 144 participants. Status unknown.
1 March 2023
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 144 |
| Start date | 26 July 2021 |
| Primary completion | 1 March 2023 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- ulinastatin — full drug profile →
Conditions studied
- ECMO — all drugs for ECMO →
- Inflammatory Response — all drugs for Inflammatory Response →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
18 and older, any sex, with ECMO or Inflammatory Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, prospective, observational cohort study. The subjects were patients who received ECMO support. According to whether ulinastatin is used in the treatment regimen (determined by the competent doctor according to the patient's condition), the patients were divided into the ulinastatin and control groups. In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. Baseline data and inflammatory markers (CRP, IL-6, IL-10, TNF-α), capillary leakage markers, routine test results, duration of ECMO use/length of hospital stay/length of ICU stay were recorded at 1, 3, and 5 days after the start of ECMO support, and patients were followed up on the 28th and 90th days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04990752
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ulinastatin
Trials testing the same drug.
- NCT07090278 — Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy · completed
- NCT03154814 — Ulinastatin Improves Postoperative Oxygenation After Cardiopulmonary Bypass · Phase 4 · completed
Other recruiting trials for ECMO
Currently open trials in the same condition.
- NCT06872021 — Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation · NA · recruiting
- NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
- NCT06274411 — Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention · NA · recruiting
- NCT06560164 — Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO · NA · recruiting
- NCT06676085 — A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation · NA · recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04990752 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 4 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04990752.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing